Magrilan (Fluoxetine Hydrochloride)

Fluoxetine blocks the serotonin transporter on presynaptic nerve terminals, preventing reuptake of serotonin. This raises serotonin levels in the synaptic cleft, enhancing serotonergic signaling and promoting neurochemical adaptations that improve mood, reduce anxiety, and lessen compulsive behaviors.

The exact dose of Magrilan is individualized by the prescribing clinician based on the patient’s diagnosis, severity of symptoms, treatment response, and any relevant medical conditions. Dosage adjustments are made during follow‑up visits to achieve optimal therapeutic effect while minimizing side effects.

The safety of fluoxetine during pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To request Magrilan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Magrilan belongs to the SSRI class, which generally offers a favorable side‑effect profile compared with older tricyclic antidepressants and monoamine oxidase inhibitors. Compared with other SSRIs, fluoxetine has a long half‑life, which may simplify dosing but also requires careful tapering to avoid discontinuation symptoms.

Magrilan tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep them in the original packaging, protect from moisture and direct light, and store out of reach of children.

Magrilan is taken orally as a tablet. It should be swallowed whole with a glass of water, with or without food, as directed by the prescriber. Patients should follow the dosing schedule provided and not alter the regimen without medical advice.

The most serious risks include the emergence of suicidal thoughts or behaviors, especially in young adults during early treatment, and serotonin syndrome, a potentially life‑threatening condition that can occur when fluoxetine is combined with other serotonergic agents. Severe allergic reactions and abnormal bleeding are also rare but critical concerns.

Magrilan should be avoided in individuals who are currently taking monoamine oxidase inhibitors, have a known hypersensitivity to fluoxetine or any tablet excipients, or have uncontrolled narrow‑angle glaucoma. Caution is also advised for patients with severe hepatic impairment or a history of bipolar disorder, where mood switching may occur.